Regimen durability in HIV‐infected children and adolescents initiating first‐line antiretroviral therapy in a large public sector HIV cohort in South Africa. Issue 6 (4th May 2018)

• Record Type: Journal Article
• Authors: Bonawitz, Rachael; Brennan, Alana T.; Long, Lawrence; Heeren, Timothy; Maskew, Mhairi; Sanne, Ian; Fox, Matthew P.
• Is Part Of: Tropical medicine & international health. Volume 23:Issue 6(2018)
• Page Start: 650
• Page End: 660
• Publication Date: 2018-05-04
• Subjects: antiretroviral therapy -- single‐drug substitution -- second‐line switch -- treatment interruption -- regimen durability -- paediatrics; thérapie antirétrovirale -- substitution d'un seul médicament -- changement de deuxième ligne -- interruption du traitement -- pérennité du régime -- pédiatrie; Tropical medicine -- Periodicals; Public health -- Periodicals; 616.988
• DOI: 10.1111/tmi.13057
• Languages: English
• ISSNs: 1360-2276

Abstract

Abstract: Introduction: In April 2010, tenofovir and abacavir replaced stavudine in public sector first‐line antiretroviral therapy (ART) for children under 20 years old in South Africa. The association of both abacavir and tenofovir with fewer side effects and toxicities compared to stavudine could translate to increased durability of tenofovir or abacavir‐based regimens. We evaluated changes over time in regimen durability for paediatric patients 3–19 years of age at eight public sector clinics in Johannesburg, South Africa. Methods: Cohort analysis of treatment‐naïve, non‐pregnant paediatric patients from 3 to 19 years old initiated on ART between April 2004 and December 2013. First‐line ART regimens before April 2010 consisted of stavudine or zidovudine with lamivudine and either efavirenz or nevirapine. Tenofovir and/or abacavir was substituted for stavudine after April 2010 in first‐line ART. We evaluated the frequency and type of single‐drug substitutions, treatment interruptions and switches to second‐line therapy. Fine and Gray competing risk regression models were used to evaluate the association of antiretroviral drug type with single‐drug substitutions, treatment interruptions and second‐line switches in the first 24 months on treatment. Results: Three hundred and ninety‐eight (15.3%) single‐drug substitutions, 187 (7.2%) treatment interruptions and 86 (3.3%) switches to second‐line therapy occurred among 2602 paediatric patients over 24‐months on ART. Overall, the rate of single‐drug substitutions started to increase in 2009, peaked in 2011 at 25% and then declined to 10% in 2013, well after the integration of tenofovir into paediatric regimens; no patients over the age of 3 were initiated on abacavir for first‐line therapy. Competing risk regression models showed patients on zidovudine or stavudine had upwards of a fivefold increase in single‐drug substitution vs. patients initiated on tenofovir in the first 24 months on ART. Older adolescents also had a two‐ to threefold increase in treatment interruptions and switches to second‐line therapy compared to younger patients in the first 24 months on ART. Conclusions: The decline in single‐drug substitutions is associated with the introduction of tenofovir. Tenofovir use could improve regimen durability and treatment outcomes in resource‐limited settings.